<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033408</url>
  </required_header>
  <id_info>
    <org_study_id>ABCS-FMT-01</org_study_id>
    <nct_id>NCT02033408</nct_id>
  </id_info>
  <brief_title>Manipulating the Microbiome in IBD by Antibiotics and FMT</brief_title>
  <acronym>FMT</acronym>
  <official_title>Manipulating the Microbiome in IBD by Antibiotics and Fecal Microbiota Transplantation (FMT): a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the etiology of Inflammatory Bowel Diseases (IBD) is closely associated with the gut
      microbiome. The results of previous studies on the effectiveness of antibiotics and fecal
      macrobiota transplantation (FMT) are contradicting.

      Aims: to evaluate the effectiveness of wide-spectrum antibiotic regimens in acute severe
      colitis in an addition to standard corticosteroid therapy (UC and isolated &quot;UC-like&quot; Crohn's
      colitis). The secondary aim is to assess the outcome of FMT in those not responding to five
      days of therapy (in either arm). As an exploratory aim, any IBD patient with a resistant
      disease to at least two immunosuppressive medications, may be treated with either
      interventions.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total PUCAI (Pediatric Ulcerative Colitis Activity Index) score</measure>
    <time_frame>at day 5 after treatment (compared between the two treatment groups).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission rates</measure>
    <time_frame>at days 7, separately at discharge, separately at day 14, and separately at 90 days.</time_frame>
    <description>defined by PUCAI&lt;10 without the need for second line therapy (anti TNF (Tumor Necrosis Factor), cyclosporine or tacrolimus) or colectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with PUCAI&lt;35 points</measure>
    <time_frame>at day 5</time_frame>
    <description>without the need for second line therapy (anti TNF, cyclosporine or tacrolimus) or colectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for second line therapy or colectomy by discharge</measure>
    <time_frame>by 90 days and at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of steroid</measure>
    <time_frame>dependency at 1 year</time_frame>
    <description>defined as a course longer than 3 month with an unsuccessful attempt to wean steroids or cumulative steroid treatment months of 4 months, during the year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for subsequent admission</measure>
    <time_frame>by 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin levels</measure>
    <time_frame>at 5 and 14 days after treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of gastrointestinal carriage of resistant organisms (VRE, ESBL)</measure>
    <time_frame>at days 5 and 14 after treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiome pattern.</measure>
    <time_frame>3 years from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of C. difficile infection</measure>
    <time_frame>at days 5 and 14 after treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Exacerbation of Ulcerative Colitis</condition>
  <condition>Ulcerative Colitis, Active Severe</condition>
  <condition>Crohn's Colitis</condition>
  <arm_group>
    <arm_group_label>Antibiotics in addition to steroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses and in addition the following antibiotics:
PO Vancomycin 250mg 4 times a day for 3 weeks (children under age 8 125mgX4/d for 3 weeks)
PO Amoxycillin 50mg per Kg divided by 3 (up to 500mg 3 times a day) - for 3 weeks
PO Metronidazole 5mg per Kg 3 times a day (up to 250mg 3 times a day) - for 3 weeks
PO Doxycycline 2mg per kg twice a day (up to 100mg twice a day) - for 3 weeks; OR- For children younger than 7 years: PO Ciprofloxacin 10mg per Kg twice a day (up to 250mg twice a day) for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroids only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>either the antibiotics and/or FMT (fecal microbiome transplant) may be administered in a non-randomized, uncontrolled open-label arm to any resistant IBD patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB (antibiotics)</intervention_name>
    <description>PO Vancomycin 250mgX4/d for 3 weeks
PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks
PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks
Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug.</description>
    <arm_group_label>Antibiotics in addition to steroids</arm_group_label>
    <arm_group_label>Open arm</arm_group_label>
    <other_name>Ciprofloxacin-Ciprodex®</other_name>
    <other_name>Doxycycline-Doxylin®</other_name>
    <other_name>Gentamycin-Gentamicin®</other_name>
    <other_name>Amoxicillin-Amoxyclav®</other_name>
    <other_name>Vancomycin-Vanco-Teva®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS (corticosteroids) Only</intervention_name>
    <description>methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)
PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks</description>
    <arm_group_label>Steroids only</arm_group_label>
    <arm_group_label>Open arm</arm_group_label>
    <other_name>Metronidazole-Flagyl®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children over the age the 2 years and adults of all ages with established diagnosis of
             UC using standard criteria (26, 27).

          -  Admission for IV steroid therapy

          -  PUCAI of at least 65 points at admission (i.e. severe attack)

          -  PUCAI&gt;45 at enrollment

          -  Ability to swallow antibiotics (pills or syrup)

        Exclusion Criteria:

          -  Change in dose or intervals of anti-TNF within the past 2 months prior to admission.

          -  Disease confined to the rectum (Proctitis).

          -  Antibiotic use in the past 4 weeks.

          -  Any known erosive inflammation anywhere in the small bowel or esophagus.

          -  Any proven infection such as positive stool culture, parasite or C. difficile, urinary
             tract infection, cellulitis, abscess, pneumonia, line-infections etc.

          -  Fever &gt;38.5, or &gt;38.0c thought to be unrelated to the inflammatory process of active
             UC.

          -  The probable need for second line medical therapy (infliximab, cyclosporine,
             tacrolimus) or colectomy within 5 days of enrollment, as judged by the caring
             physician.

          -  Known allergy to more than one antibiotic regimen from the list below.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Turner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hospital for Sick Children (SickKids)</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Children and Adolescents Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Cener</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Napoli &quot;Federico II&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapienza University of Rome</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy Children's Hospital in Krakow</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya Málaga</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2014</study_first_posted>
  <last_update_submitted>February 4, 2018</last_update_submitted>
  <last_update_submitted_qc>February 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBD: Inflammatory Bowel Diseases</keyword>
  <keyword>CD: Crohn's Disease</keyword>
  <keyword>UC: Ulcerative Colitis</keyword>
  <keyword>ASC: Acute Severe Colitis</keyword>
  <keyword>FMT: Fecal Microbiota Transplantation</keyword>
  <keyword>PUCAI: Pediatric Ulcerative Colitis Activity Index</keyword>
  <keyword>Ciprofloxacin, Doxycycline, Gentamycin, amoxicillin, vancomycin, metronidazole,ciprofloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

